| Decentralized Clinical Trials (DCT) Expanding Globally—Korea Takes Its First Steps Amid Regulatory Challenges
| New Challenges in DCT: Data Quality Issues, Higher Patient Dropout, and Limited Researcher-Patient Communication
| JNPMEDI’s ‘Maven eCOA’ Maximizes Clinical Trial Efficiency and Overcomes DCT Limitations
| Applied to Welt Digital Therapeutics’ WELT-I, Korea’s First Musculoskeletal Digital Therapeutic
With decentralized clinical trials (DCT) gaining traction worldwide due to benefits such as reduced costs and improved patient convenience, Korea—previously hindered by regulatory barriers—is now beginning to take its first steps in this space.
In January, the Korean government announced plans to establish a domestic DCT model by conducting six clinical trials related to mild diseases by 2027.
As the global and domestic DCT markets continue to grow, it is crucial to anticipate and address potential challenges in this environment. Key issues include declining data quality, increased patient dropout rates, and limited communication between researchers and patients, all of which pose significant obstacles to the successful implementation of DCT.
On March 12, JNPMEDI (CEO KwunHo Jeong) announced that the company is actively utilizing its Maven eCOA solution to maximize efficiency and overcome the challenges of DCT.
‘Maven eCOA’ minimizes errors that may occur when patients enter data manually. By providing data validation features such as query settings, it helps researchers maintain data accuracy and consistency. This reduces input errors and enables more effective data quality management.
Additionally, its patient-centered design significantly improves compliance. In DCT, active patient participation is essential, but complex data entry processes and inconvenient user interfaces (UIs) can lead to high dropout rates. Maven eCOA addresses this with an intuitive UI and reminder functions that encourage survey participation, significantly enhancing compliance. These features are particularly valuable in long-term clinical trials, where sustained patient engagement is critical.
Beyond patient data entry, Maven eCOA strengthens researcher-patient connectivity and real-time monitoring to overcome the limitations of DCT. Traditional DCT environments often lack real-time insights into patient conditions, increasing the risk of data discontinuity. However, Maven eCOA’s dashboard provides an intuitive monitoring interface, allowing researchers to analyze patient data swiftly and take necessary actions when needed.
JNPMEDI’s Maven eCOA is already demonstrating its value through various successful applications in the Korean DCT market. One notable example is Welt’s digital therapeutic (DTx) ‘WELT-I’, Korea’s second officially approved digital therapeutic. WELT-I utilized Maven eCOA as part of its confirmatory clinical trial process, which was conducted under a DCT model—an industry first in Korea. JNPMEDI’s Maven DCT Suite solutions, including Maven eCOA, played a crucial role in collecting and validating efficacy and safety data for regulatory approval.
Another case is EverEx’s musculoskeletal digital therapeutic, ‘MORA Cure’, the first digital therapeutic in Korea to receive regulatory approval for a confirmatory clinical trial in the musculoskeletal field. During the clinical trial, Maven eCOA facilitated patient-centered data collection, ensuring both efficacy and safety assessments while enhancing patient convenience.
JNPMEDI CEO KwunHo Jeong stated, “As the global DCT market continues to grow, Korea must accelerate its adoption. JNPMEDI is committed to advancing research and development in DCT-based clinical trial solutions like Maven eCOA to expand our presence in both domestic and international markets.”
He added, “By collaborating with various partners, we aim to enhance clinical trial quality and patient engagement, ultimately positioning JNPMEDI as a leader in Korea’s DCT market with innovative solutions.”
| Decentralized Clinical Trials (DCT) Expanding Globally—Korea Takes Its First Steps Amid Regulatory Challenges
| New Challenges in DCT: Data Quality Issues, Higher Patient Dropout, and Limited Researcher-Patient Communication
| JNPMEDI’s ‘Maven eCOA’ Maximizes Clinical Trial Efficiency and Overcomes DCT Limitations
| Applied to Welt Digital Therapeutics’ WELT-I, Korea’s First Musculoskeletal Digital Therapeutic
With decentralized clinical trials (DCT) gaining traction worldwide due to benefits such as reduced costs and improved patient convenience, Korea—previously hindered by regulatory barriers—is now beginning to take its first steps in this space.
In January, the Korean government announced plans to establish a domestic DCT model by conducting six clinical trials related to mild diseases by 2027.
As the global and domestic DCT markets continue to grow, it is crucial to anticipate and address potential challenges in this environment. Key issues include declining data quality, increased patient dropout rates, and limited communication between researchers and patients, all of which pose significant obstacles to the successful implementation of DCT.
On March 12, JNPMEDI (CEO KwunHo Jeong) announced that the company is actively utilizing its Maven eCOA solution to maximize efficiency and overcome the challenges of DCT.
‘Maven eCOA’ minimizes errors that may occur when patients enter data manually. By providing data validation features such as query settings, it helps researchers maintain data accuracy and consistency. This reduces input errors and enables more effective data quality management.
Additionally, its patient-centered design significantly improves compliance. In DCT, active patient participation is essential, but complex data entry processes and inconvenient user interfaces (UIs) can lead to high dropout rates. Maven eCOA addresses this with an intuitive UI and reminder functions that encourage survey participation, significantly enhancing compliance. These features are particularly valuable in long-term clinical trials, where sustained patient engagement is critical.
Beyond patient data entry, Maven eCOA strengthens researcher-patient connectivity and real-time monitoring to overcome the limitations of DCT. Traditional DCT environments often lack real-time insights into patient conditions, increasing the risk of data discontinuity. However, Maven eCOA’s dashboard provides an intuitive monitoring interface, allowing researchers to analyze patient data swiftly and take necessary actions when needed.
JNPMEDI’s Maven eCOA is already demonstrating its value through various successful applications in the Korean DCT market. One notable example is Welt’s digital therapeutic (DTx) ‘WELT-I’, Korea’s second officially approved digital therapeutic. WELT-I utilized Maven eCOA as part of its confirmatory clinical trial process, which was conducted under a DCT model—an industry first in Korea. JNPMEDI’s Maven DCT Suite solutions, including Maven eCOA, played a crucial role in collecting and validating efficacy and safety data for regulatory approval.
Another case is EverEx’s musculoskeletal digital therapeutic, ‘MORA Cure’, the first digital therapeutic in Korea to receive regulatory approval for a confirmatory clinical trial in the musculoskeletal field. During the clinical trial, Maven eCOA facilitated patient-centered data collection, ensuring both efficacy and safety assessments while enhancing patient convenience.
JNPMEDI CEO KwunHo Jeong stated, “As the global DCT market continues to grow, Korea must accelerate its adoption. JNPMEDI is committed to advancing research and development in DCT-based clinical trial solutions like Maven eCOA to expand our presence in both domestic and international markets.”
He added, “By collaborating with various partners, we aim to enhance clinical trial quality and patient engagement, ultimately positioning JNPMEDI as a leader in Korea’s DCT market with innovative solutions.”